GLP-1 and MASH: When weight loss isn't the whole story.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 42413474.
- Also identified by DOI 10.1016/j.cmet.2026.06.005.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Metabolic dysfunction-associated steatohepatitis (MASH) remains a major unmet clinical challenge. A new study by Gonzalez-Rellan et al.<sup>1</sup> shows that glucagon-like peptide 1 (GLP-1) receptors on intrahepatic sinusoidal endothelial cells are key mediators of semaglutide's weight loss-independent hepatoprotective effects, reframing our understanding of how GLP-1-based therapies act within the diseased liver.
Medical subject headings
- Weight Loss
- Glucagon-Like Peptide 1
- Fatty Liver